Alger Health Sciences A
111 Fifth Avenue New York NY 10003
Map
Phone: 800-992-3863
| Category: | Health | | Fund Family: | Alger | | Net Assets: | 177.96M | | Year-to-Date Return: | 21.01% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 01-May-02 |
|
Dan C. Chung
Lead Manager since
07-Oct-05 | | | Chung is chief executive officer and chief investment officer of Fred Alger Management, Inc. He has 15 years of experience and has been with Alger since 1994. He was named chief investment officer in September 2001, president in 2003, and CEO in 2006. He is portfolio manager of the Alger MidCap Growth, Alger Health Sciences, Alger LargeCap Growth, Alger SMidCap Growth, and Alger Analyst portfolios. |
| Min Initial Investment: | $1,000 | | Min Initial Investment, IRA: | $500 | | Min Initial Investment, AIP: | $500 | | Min Subsequent Investment: | $50 | | Min Subsequent Investment, IRA: | $50 | | Min Subsequent Investment, AIP: | $50 |
|
| |
| The investment seeks long-term capital appreciation. The fund normally invests at least 80% of net assets plus any borrowings for investment purposes in equity securities of companies of any market capitalization that are engaged in the health sciences sector. It can leverage, that is, borrow money to buy additional securities. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(18-Dec-07):
| 1.49 | | Annual Holdings Turnover
| YFT_NOT_APPLICABLE_ABBREVIATION | | Average for Category:
| 109.30% |
|
| Expense | AHSAX | Category
Avg | | Total Expense Ratio: | 1.31%
| 1.67% | | Max 12b1 Fee: | 0.25%
| N/A | | Max Front End Sales Load: | 5.25%
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 918 | $716 | | 5 Yr Expense Projection*: |
$ 1,205 | $1,069 | | 10 Yr Expense Projection*: |
$ 2,021 | $2,090 |
|
|
0.17% Nasdaq 0.00%
Profile
